Rengalin tab for the races. 20 pc

Description

Composition
Active substance:
Antibodies to bradykinin affinity-purified – 0,006 g *
Antibodies to histamine affinity-purified – 0,006 g *
Antibodies to morphine affinity-purified – 0,006 g *
* Applied to the isomalt as a mixture of three aqueous-alcoholic active substance dilutions diluted respectively at 10012, 10030, 10050 times.
Excipients:
Isomalt 0.506 g, 0.0275 g of microcrystalline cellulose, magnesium stearate 0.0055 g of citric acid anhydrous 0.005225 g colloidal silicon dioxide 0.00275 g, 0.00275 g of sodium cyclamate, sodium saccharin 0.000275 g
Description:
Ploskotsilindricheskoy tablet form with a facet, with the mark on one flat side, with integral edges, from white to almost white color.
On the flat side coated with Valium inscription MATERIA MEDICA, on the other flat side applied RENGALIN inscription.
Product form:
Lozenges. 10 tablets in blisters of PVC film and aluminum foil.
2 contour of cellular packaging together with instructions for medical application is placed in a pile of cardboard.
Contraindications
Increased individual sensitivity to the drug. Rengalin not recommended for use in children younger than 3 years due to lack of efficacy and safety data.
Dosage
18 mg
Indications
Acute and chronic respiratory diseases, accompanied by cough and bronchospasm. Productive and non-productive cough with influenza and SARS, acute pharyngitis, laryngotracheitis, acute obstructive laryngitis, chronic bronchitis and other inflammatory and infectious-allergic diseases of the upper and lower respiratory tract.
Interaction with other drugs
Incompatibilities with other drugs has not yet been registered.
Overdose
Accidental overdosing possible diarrheal phenomena caused by members of the formulation excipients.
pharmachologic effect
Pharmacological group:
Other cold preparations
Pharmacodynamics:
It is shown experimentally that the components of the drug activity is modified ligand-receptor interaction of endogenous regulators of the corresponding receptors: morphine antibody – to opiate receptors; Antibodies to the histamine – with H1 histamine receptors; antibodies to bradykinin – bradykinin receptors with B1; wherein the combined use of the components leads to increased antitussive effect.
Furthermore antitussive action, due to the complex preparation of its constituent components having antiinflammatory, antiedematous, antiallergic, spasmolytic (antibody to histamine, bradykinin antibodies) and analgesic effect (antibody to morphine).
Complex preparation Rengalin through modification-dependent activation of histamine H1-receptors and bradykinin-dependent activation B2 – receptor selectively reduces the excitability of the cough center of the medulla oblongata, inhibits central links cough reflex. Inhibiting pain sensitivity centers in the thalamus, blocks the transmission of pain impulses to the cerebral cortex. Inhibits the flow of pain impulses from the periphery due to the reduction of release of tissue and plasma algogenov (histamine, bradykinin, prostaglandins, etc.). In contrast to narcotic analgesics causes no respiratory depression, drug addiction, has no narcogene and soporific effect.
Facilitates manifestations of acute pharyngitis, laryngitis, and bronchitis, reducing bronchoconstriction. Relieves systemic and local symptoms of allergic reactions due to the influence on the synthesis and release of histamine and bradykinin from mast cells.
Pharmacokinetics:
Sensitivity modern physico-chemical methods of analysis (gas-liquid chromatography, high performance liquid chromatography, gas chromatography-mass spectrometry) does not allow to evaluate the content of active components Rengalin drug in biological fluids, organs and tissues, making it impossible technically pharmacokinetics study.
Pregnancy and breast-feeding
Security applications Rengalina in pregnancy and lactation has not been studied. If necessary, dosing should be considered risk / benefit ratio.
Conditions of supply of pharmacies
Without recipe
side effects
Possible reactions of individual hypersensitivity to the drug.
special instructions
Rengalin does not affect the ability to drive vehicles and other potentially dangerous machinery.
Effect of the drug for medical use in the ability to operate vehicles, machinery
Rengalin does not affect the ability to drive vehicles and other potentially dangerous machinery.
Storage conditions
In the dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Inside. In one process – one tablet (kept in the mouth until complete dissolution). Apply 1-2 tablets 3 times a day outside meal. Depending on the severity of the condition in the first three days of reception frequency can be increased to 4-6 times per day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist